Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A proteomic approach using a cleavable ICAT reagent and nano-LC ESI tandem mass spectrometry was used to perform protein profiling of core RBC membrane skeleton proteins between sickle cell patients (SS) and controls (AA), and determine the efficacy of this technology. The data was validated through Peptide/Protein Prophet and protein ratios were calculated through ASAPratio. Through an ANOVA test, it was determined that there is no significant difference in the mean ratios from control populations (AA1/AA2) and sickle cell versus control populations (AA/SS). The mean ratios were not significantly different from 1.0 in either comparison for the core skeleton proteins (alpha spectrin, beta spectrin, band 4.1 and actin). On the natural-log scale, the variation (standard deviation) of the method was determined to be 14.1% and the variation contributed by the samples was 13.8% which together give a total variation of 19.7% in the ratios.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472844 | PMC |
| http://dx.doi.org/10.2478/s11658-006-0026-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving access to healthcare services for sickle cell disease patients in Nigeria: perspectives and views of healthcare professionals.
Front Health Serv
August 2025
Department of Medical Laboratory Sciences, University of Nigeria, Enugu, Nigeria.
Introduction: In sub-Saharan Africa, the burden of sickle cell disease remains high. With annual sickle cell births of about 150,000, Nigeria is reported to have the highest prevalence of the disease globally. This study aimed to explore the views and perspectives of healthcare professionals regarding access to healthcare services for sickle cell disease.
View Article and Find Full Text PDFSpirometry Interpretation in Children With Sickle Cell Disease: GLI Global Versus Race-Specific Normative Equations.
Am J Hematol
September 2025
Division of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
More than pain: Speech, language, neurocognitive, and hearing issues among children with sickle cell disease.
J Natl Med Assoc
September 2025
Communication Equity Outcomes Laboratory, Department of Speech, Language and Hearing Sciences, University of Florida, Gainesville, FL, United States.
Importance: Significant advancements have been made in the management of sickle cell disease (SCD); an inherited blood disorder most prevalent among African Americans. While chronic pain is a hallmark of SCD and has been the primary focus of treatment, contemporary literature highlights the potential presence of developmental issues related to speech, language, neurocognitive, and auditory abilities that are often overlooked in SCD management.
Observations: This paper explores the spectrum of communication-related challenges that specifically affect children with SCD and fall within the scope of practice for speech-language pathologists (SLPs) and audiologists (AUDs).
Biological Parenthood Rates Among Men with Sickle Cell Disease.
Blood Adv
September 2025
Nationwide Children's Hospital Research Institute, Columbus, Ohio, United States.
Vaccine Immunity Against Pneumococcus in Children With Sickle Cell Disease: A Retrospective Single-center Study.
Pediatr Infect Dis J
September 2025
Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Unit of Immunology, Vaccinology, and Rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Background And Aims: Sickle cell disease (SCD) patients are at a higher risk of pneumococcal invasive diseases. Vaccination is the central strategy for protecting these children, along with penicillin prophylaxis. However, it is unclear how often these children should be revaccinated with pneumococcal vaccines.
View Article and Find Full Text PDF